SCHEMBL2386233

SCHEMBL2386233

COc1cccc2oc(-c3cc(Br)cnc3N)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 3/20 0.41
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MET P08581 2/20 0.39
MAPT P10636 2/20 0.39
SHMT2 P34897 1/20 0.38
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
ATR Q13535 1/20 0.37
MCHR1 Q99705 1/20 0.36
FYN P06241 4/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
HPGD P15428 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385451 0.88 F2RL3 (0.37) F2RL3KDM4EALDH1A1METMAPT
SCHEMBL2385744 0.85 F2RL3 (0.40) F2RL3KDM4EALDH1A1MAPTSHMT2
SCHEMBL2387707 0.81 TOP2A (0.44) F2RL3METMAPTATRMEN1
SCHEMBL2386983 0.81 MET (0.41) KDM4EMETMAPTMEN1KMT2A
SCHEMBL2384705 0.81 KDM4E (0.44) KDM4EALDH1A1METMAPTSHMT2
SCHEMBL2385969 0.79 MET (0.39) KDM4EALDH1A1METMAPTATR
SCHEMBL2384707 0.76 MET (0.63) KDM4EALDH1A1METMAPTMEN1
SCHEMBL14764726 0.74 NPC1 (0.37) KDM4EALDH1A1MAPTPSEN1PSEN2
SCHEMBL29858095 0.74 FYN (0.49) ALDH1A1SHMT2FYNMEN1KMT2A
SCHEMBL16974099 0.74 FYN (0.49) ALDH1A1SHMT2FYNMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017611-B2 Pyridine and pyrazine derivatives -083 ASTRAZENECA AB (SE) 2011-09-13 US disclosed
EP-2215085-B1 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-09-07 EP disclosed
EP-2215085-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2010-08-11 EP disclosed
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 ASTRAZENECA AB (SE) 2009-05-07 US disclosed
WO-2009053737-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 MKI67, CCND3, CCND1 F2RL3 2836/4885KDM4E 2374/4885ALDH1A1 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.